Prothena Corp. PLC will cut more than half of its workforce under recently announced reorganization plans that were set into motion after the failure of its lead pipeline candidate NEOD001 in April 2018.
Prothena had been developing NEOD001 as a treatment for amyloidosis – a diverse group of diseases, of acquired or hereditary origin,